DK0482539T3 - Peptidforbindelser, fremgangsmåder til fremstilling deraf og farmaceutisk præparat indeholdende disse - Google Patents
Peptidforbindelser, fremgangsmåder til fremstilling deraf og farmaceutisk præparat indeholdende disseInfo
- Publication number
- DK0482539T3 DK0482539T3 DK91117889.5T DK91117889T DK0482539T3 DK 0482539 T3 DK0482539 T3 DK 0482539T3 DK 91117889 T DK91117889 T DK 91117889T DK 0482539 T3 DK0482539 T3 DK 0482539T3
- Authority
- DK
- Denmark
- Prior art keywords
- suitable substituent
- alkyl
- processes
- pharmaceutical compositions
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 pyrazolopyridyl Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Electroluminescent Light Sources (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909023116A GB9023116D0 (en) | 1990-10-24 | 1990-10-24 | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0482539T3 true DK0482539T3 (da) | 1997-01-06 |
Family
ID=10684270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91117889.5T DK0482539T3 (da) | 1990-10-24 | 1991-10-20 | Peptidforbindelser, fremgangsmåder til fremstilling deraf og farmaceutisk præparat indeholdende disse |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0482539B1 (da) |
| JP (1) | JP3206764B2 (da) |
| KR (1) | KR920008065A (da) |
| CN (2) | CN1038939C (da) |
| AT (1) | ATE146480T1 (da) |
| AU (1) | AU647534B2 (da) |
| CA (1) | CA2054097A1 (da) |
| DE (1) | DE69123697T2 (da) |
| DK (1) | DK0482539T3 (da) |
| ES (1) | ES2095283T3 (da) |
| FI (1) | FI914961A7 (da) |
| GB (1) | GB9023116D0 (da) |
| GR (1) | GR3022137T3 (da) |
| HU (2) | HUT59163A (da) |
| IE (1) | IE913599A1 (da) |
| NO (1) | NO914171L (da) |
| PT (1) | PT99317B (da) |
| RU (1) | RU2073683C1 (da) |
| ZA (1) | ZA918011B (da) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420297A (en) * | 1990-10-24 | 1995-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having substance P antagonistic activity |
| EP1082959A1 (en) | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonists for the treatment of depression |
| US5328927A (en) * | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
| DE4243496A1 (de) * | 1992-09-03 | 1994-03-10 | Boehringer Ingelheim Kg | Neue Dipeptidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DE59309867D1 (de) * | 1992-09-03 | 1999-12-16 | Boehringer Ingelheim Pharma | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
| IT1256623B (it) * | 1992-12-04 | 1995-12-12 | Federico Arcamone | Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche |
| FR2700472B1 (fr) | 1993-01-19 | 1995-02-17 | Rhone Poulenc Rorer Sa | Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2. |
| US5674889A (en) * | 1993-02-22 | 1997-10-07 | Merck, Sharp & Dohme, Ltd. | Aromatic compounds, compositions containing them and their use in therapy |
| WO1994020126A1 (en) * | 1993-03-03 | 1994-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Use of peptides for the manufacture of a medicament |
| US5635510A (en) * | 1993-05-06 | 1997-06-03 | Merrell Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines |
| WO1995000536A1 (en) * | 1993-06-22 | 1995-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds |
| US5455262A (en) * | 1993-10-06 | 1995-10-03 | Florida State University | Mercaptosulfide metalloproteinase inhibitors |
| MX9605128A (es) * | 1994-05-07 | 1997-08-30 | Boehringer Ingelheim Kg | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos. |
| MX9701305A (es) | 1994-08-25 | 1998-05-31 | Merrell Pharma Inc | Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas. |
| US5830868A (en) * | 1994-09-13 | 1998-11-03 | Warner-Lambert Company | Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase |
| CN1098255C (zh) * | 1995-04-13 | 2003-01-08 | 阿温蒂斯药物公司 | 新的具有速激肽受体拮抗活性的取代的哌嗪衍生物 |
| US6211199B1 (en) | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| US6423704B2 (en) | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
| US6194406B1 (en) | 1995-12-20 | 2001-02-27 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease |
| US5932571A (en) * | 1996-02-21 | 1999-08-03 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases |
| US5998439A (en) * | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
| US5922737A (en) * | 1996-02-21 | 1999-07-13 | Hoechst Marion Roussel, Inc. | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases |
| US6423689B1 (en) | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
| CN1310724A (zh) * | 1998-07-23 | 2001-08-29 | 阿克佐诺贝尔公司 | 用于自身免疫疾病的免疫疗法中的新型肽 |
| MXPA02004330A (es) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| KR100821410B1 (ko) | 2000-07-11 | 2008-04-10 | 에이엠알 테크놀로지, 인크. | 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도 |
| UA91341C2 (ru) | 2004-07-15 | 2010-07-26 | Амр Текнолоджи, Інк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
| UA95454C2 (uk) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| AR064777A1 (es) | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| AU2010247763B2 (en) | 2009-05-12 | 2015-12-24 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| WO2013165816A2 (en) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| ME02925B (me) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Kompozicije i postupci za liječenje kancera |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲hdm2抑制劑之經取代咪唑吡啶 |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033288A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4395401A (en) * | 1981-09-09 | 1983-07-26 | Smithkline Beckman Corporation | Renally active dipeptides |
| US5187156A (en) * | 1988-03-16 | 1993-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same |
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
-
1990
- 1990-10-24 GB GB909023116A patent/GB9023116D0/en active Pending
-
1991
- 1991-10-07 ZA ZA918011A patent/ZA918011B/xx unknown
- 1991-10-16 IE IE359991A patent/IE913599A1/en not_active Application Discontinuation
- 1991-10-18 AU AU85925/91A patent/AU647534B2/en not_active Ceased
- 1991-10-20 DE DE69123697T patent/DE69123697T2/de not_active Expired - Fee Related
- 1991-10-20 ES ES91117889T patent/ES2095283T3/es not_active Expired - Lifetime
- 1991-10-20 EP EP91117889A patent/EP0482539B1/en not_active Expired - Lifetime
- 1991-10-20 DK DK91117889.5T patent/DK0482539T3/da active
- 1991-10-20 AT AT91117889T patent/ATE146480T1/de not_active IP Right Cessation
- 1991-10-22 FI FI914961A patent/FI914961A7/fi not_active Application Discontinuation
- 1991-10-22 KR KR1019910018577A patent/KR920008065A/ko not_active Ceased
- 1991-10-22 HU HU913331A patent/HUT59163A/hu unknown
- 1991-10-23 CA CA002054097A patent/CA2054097A1/en not_active Abandoned
- 1991-10-23 PT PT99317A patent/PT99317B/pt not_active IP Right Cessation
- 1991-10-23 NO NO91914171A patent/NO914171L/no unknown
- 1991-10-23 RU SU915010105A patent/RU2073683C1/ru active
- 1991-10-23 CN CN91109851A patent/CN1038939C/zh not_active Expired - Lifetime
- 1991-10-24 JP JP34387291A patent/JP3206764B2/ja not_active Expired - Fee Related
-
1995
- 1995-06-22 HU HU95P/P00392P patent/HU211611A9/hu unknown
-
1996
- 1996-08-14 CN CN96111367A patent/CN1148503A/zh active Pending
- 1996-12-23 GR GR960403576T patent/GR3022137T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR920008065A (ko) | 1992-05-27 |
| EP0482539A2 (en) | 1992-04-29 |
| EP0482539A3 (en) | 1992-08-26 |
| EP0482539B1 (en) | 1996-12-18 |
| JP3206764B2 (ja) | 2001-09-10 |
| IE913599A1 (en) | 1992-05-22 |
| FI914961A7 (fi) | 1992-04-25 |
| CN1060848A (zh) | 1992-05-06 |
| CA2054097A1 (en) | 1992-04-25 |
| ZA918011B (en) | 1992-07-29 |
| GR3022137T3 (en) | 1997-03-31 |
| FI914961A0 (fi) | 1991-10-22 |
| CN1148503A (zh) | 1997-04-30 |
| NO914171L (no) | 1992-04-27 |
| AU647534B2 (en) | 1994-03-24 |
| HUT59163A (en) | 1992-04-28 |
| NO914171D0 (no) | 1991-10-23 |
| AU8592591A (en) | 1992-04-30 |
| CN1038939C (zh) | 1998-07-01 |
| RU2073683C1 (ru) | 1997-02-20 |
| DE69123697T2 (de) | 1997-04-17 |
| ATE146480T1 (de) | 1997-01-15 |
| PT99317A (pt) | 1992-09-30 |
| HU913331D0 (en) | 1992-01-28 |
| JPH04297492A (ja) | 1992-10-21 |
| DE69123697D1 (de) | 1997-01-30 |
| PT99317B (pt) | 1999-04-30 |
| GB9023116D0 (en) | 1990-12-05 |
| ES2095283T3 (es) | 1997-02-16 |
| HU211611A9 (en) | 1995-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0482539T3 (da) | Peptidforbindelser, fremgangsmåder til fremstilling deraf og farmaceutisk præparat indeholdende disse | |
| DE69015244D1 (de) | Peptidverbindungen, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten. | |
| DK0443132T3 (da) | Peptider med tachykininantagonistaktivitet, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende samme | |
| DK126389A (da) | Peptidforbindelser | |
| DK0467248T3 (da) | Pyrazolopyridinforbindelse og fremgangsmåder til fremstilling heraf | |
| IL99443A0 (en) | Heterocyclic derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| DK96786A (da) | Aminosyrederivater | |
| IL90424A0 (en) | Cephem derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
| ATE48001T1 (de) | Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate. | |
| EP0420086A3 (en) | Pyrimidoindole derivatives and processes for preparation thereof | |
| NO903084L (no) | Farmasoeytisk anvendbare thiazolderivater og fremgangsmaatefor deresfremstilling. |